1198207-11-2

Upstream product

• 1198207-20-3 C₃₄H₃₅N₃O₄ 
• 1198207-22-5 C₃₄H₃₅N₃O₄ 
• 80177-94-2 1L-(1,3/2,4)-1,2,3,4-Tetrakis(benzyloxy)-5-cyclohexen 
• 1198207-09-8 N-((1S)-1-((4S,5R)-2,2-dimethyl-5-tetradecyl-1,3-dioxolan-4-yl)-2-((1S,2S,3R,4R,5S)-2,3,4,5-tetrakis(benzyloxy)cyclohexylamino)ethyl)-2-nitrobenzenesulfonamide 
• 1198207-07-6 (1S,2S,3R,4R,5S)-2,3,4,5-tetrakis(benzyloxy)cyclohexanamine 
• 143396-09-2 (1R,2S,3R,4R,5S)-2,3,4,5-tetrakis(benzyloxy)cyclohexanol 

Downstream Products

• 1198207-13-4 (2S,3S,4R)-(3,4-isopropylidenedioxy-1-(1'S,2'S,3'R,4'R,5'S)-2',3',4',5'-tetrabenzyloxycyclohexylaminooctadecan-2-yl)hexacosanamide 

Relevant academic research and scientific papers

AMINOCYCLITOL COMPOUNDS, PROCESS FOR OBTAINING THEM AND USES

Aminocyclitol compounds and uses thereof as pharmaceutical compositions for the treatment of diseases associated with alterations in iNKT cells, more specifically autoimmune diseases, cancer, infections caused by pathogenic microorganisms or inflammatory

AMINOCYCLITOL COMPOUNDS, PROCEDURE FOR THE OBTAINMENT AND USES

Aminocyclitol compounds, process for obtaining them and uses Aminocyclitol compounds and uses thereof as pharmaceutical compositions for the treatment of diseases associated with alterations in iNKT cells, more specifically autoimmune diseases, cancer, in